As the Exchanges mature and enrollment in QHPs expands, we will consider reporting the QRS at more granular levels (that is, QHP metal levels as defined in section 1302(d)(1) of the Affordable Care Act). We will also consider the development of a quality rating system applicable to other Exchange offerings, such as stand-alone dental plans, catastrophic plans and health care saving accounts.

VI. Collection of Information Requirements

This document does not impose information collection and recordkeeping requirements. However, it does make reference to an information collection activity. The aforementioned Enrollee Satisfaction Survey is currently seeking OMB approval via notice and comment periods separate from this proposed notice. The 60-day **Federal Register** notice published on June 28, 2013. Additionally, in future rulemaking, we will identify information collection requirements associated with the QRS and solicit public comment at that time.

Dated: November 6, 2013.

Marilyn Tavenner,

Administrator, Centers for Medicare & Medicaid Services. [FR Doc. 2013–27649 Filed 11–14–13; 4:15 pm] BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request: NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI)

SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request for review and

approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on August 22, 2013, Vol. 78, P. 52204 and allowed 60days for public comment. There were no public comments received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@ omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

FOR FURTHER INFORMATION: To obtain a copy of the data collection plans and instruments or request more information on the proposed project contact: CAPT Michael Montello, Pharm. D., MBA, Cancer Therapy Evaluation Program, Operations and Informatics Branch, 9609 Medical Center Drive, Rockville, MD 20850 or call non-toll-free number 240–276–6080 or Email your request, including your address to: *mike.montello@nih.gov.* Formal requests for additional plans and instruments must be requested in writing.

Proposed Collection: NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI), 0925–0625, Expiration Date 1/31/2014, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information Collection: The National Cancer Institute (NCI) Central Institutional Review Board (CIRB) provides a centralized approach to human subject protection and provides a cost efficient approach avoiding duplication of effort at each institution. The CIRB provides the services of a fully constituted IRB and provides a comprehensive and efficient mechanism to meet regulatory requirements pertaining to human subject protections including: initial reviews, continuing reviews, review of amendments, and adverse events. The Initiative consists of three central IRBs: Adult CIRB—late phase emphasis, Adult CIRB—early phase emphasis, and Pediatric CIRB. CIRB membership includes oncology physicians, surgeons, nurses, patient advocates, ethicists, statisticians, pharmacists, attorneys and other health professionals. The benefits of the CIRB Initiative reaches research participants, investigators and research staff, Institutional Review Boards (IRB), and Institutions. Benefits include: study participants having dedicated review of NCI-sponsored trials for participant protections, access to more trials more quickly and access to trials for rare diseases, accrual to trials begin more rapidly, ease of opening trials, elimination of need to submit study materials to local IRBs, and elimination of the need for a full board review. The benefits to the National Clinical Trials Network and Experimental Therapy-Clinical Trials Network include a cost efficient approach that avoids duplication of efforts at each institution. A variety of information collection tools are needed to support NCI's CIRB activities which include: worksheets, forms and a survey that is provided to all customers contacting the CIRB helpdesk.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 2,199.

ESTIMATES OF ANNUAL BURDEN HOURS

Form name	Type of respondents	Number of respondents	Frequency of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CIRB Customer Satisfaction Survey	Participants/Board Members.	1,500	1	10/60	250
Request for 30 Day Website Access Form	Participants	25	1	10/60	4
Authorization Agreement and Division of Respon- sibilities between the NCI CIRB and Signatory Institution.	Participants	340	1	30/60	170
NCI CIRB Signatory Enrollment Form	Participants	40	1	4	160
IRB Staff at Signatory Institution's IRB	Participants	25	1	10/60	4
Investigator at Signatory Institution	Participants	65	1	10/60	11
Research Staff at Signatory Institution	Participants	65	1	10/60	11

ESTIMATES OF ANNUAL BURDEN HOURS-Continued

Investigator al Affiliate Institution with an IB Participants 25 1 1060 4 Investigator al Affiliate Institution without an IB Participants 25 1 1060 4 Institutional Contact for Signatory Institution Participants 25 1 1060 4 Component Institution al Signatory Institution Participants 25 1 1060 4 Faultitate Institution al Signatory Institution Participants 25 1 1060 4 Faultitate Institution al Signatory Institution Participants 25 1 1060 4 Faultitate Institution without an IB Participants 20 1 2060 40 Audre Context Institution Without an IB Participants 120 1 2060 73 Stard Consure on Transfer of Stardy Review Rev Participants 120 1 1060 20 Ad or Review Signatory and/component Institution Personnel Participants 120 1 1060 20 Contence Militate Institution Personnel Partici	Form name	Type of respondents	Number of respondents	Frequency of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Research Staff at Affiliate Institution without an IRB Participants 25 1 10/60 4 Research Staff at Affiliate Institution without an IRB Participants 25 1 10/60 4 Research Staff at Affiliate Institution without an IRB Participants 25 1 10/60 14 Research Staff at Affiliate Institution Participants 25 1 10/60 14 Component Institution Participants 25 1 10/60 4 Affiliate Institution without an IRB Participants 25 1 10/60 4 Affiliate Institution without an IRB Participants 25 1 10/60 4 Affiliate Institution Worksheet About Local Context 20 1 20/60 40 Local Context Participants 20 1 10/60 20 10/60 20 Study Specific Worksheet About Local Context Participants 20 1 10/60 20 Continuing Noncomplance Repearing Form. 10/60 10/60 20<	Investigator at Affiliate Institution with an IRB	Participants	25	1	10/60	4
investigator at Affiliate Institution without an IBB. Participants 25 1 10/60 4 Rescarch Staff at Affiliate Institution at Comparing Institution and Signatory Institution. Participants 65 1 10/60 1 IRB at Affiliate Institution at Comparing Institution and Signatory Institution Worksheet About Local Context. 120 1 20/60 40 Anual Signatory Institution Worksheet About Local Context. 120 1 20/60 40 Louid-Specific Worksheet About Local Context. Participants 120 1 20/60 40 Add or Remove Signatory and/or Component Institution Personnell. Participants 120 1 10/60 20 Add or Remove Signatory and/or Component Institution Personnell Participants 120 1 10/60 20 Charling National Problem Problem Problem Signatory and/or Component Institution Personnell Participants 120 1 10/60 20 Add or Remove Signatory and/or Component Institution Personnell Participants						
Institutional Contact for Signatory Institution Participants 65 1 10/60 41 Ideal A fillad institution Participants 25 1 10/60 44 Comporter Institution Participants 25 1 10/60 44 Failibilitation Participants 25 1 10/60 45 Table A fillad in Statution Participants 200 1 10/60 10 Annual Signatory Institution Worksheet About Participants 220 20/60 73 Annual Signatory Institution Participants 120 1 10/60 20 Study Specific Worksheet About Participants 120 1 10/60 20 Study Specific Worksheet About Participants 120 1 10/60 20 Atdor Personel Participants 120 1 10/60 20 Add or Remove Componel Institution Participants 120 1 10/60 20 Add or Remove Altitals Institution Participant	Investigator at Affiliate Institution without an IRB		25	1	10/60	4
IFB at Signatory Institution	Research Staff at Affiliate Institution without an IRB	Participants	25	1	10/60	4
Component Institution al Signatory Institution Participants 65 1 10/60 11 Affiliat Institution without an IRB Participants 25 1 10/60 4 Affiliat Institution without an IRB Participants 25 1 10/60 4 Affiliat Institution without an IRB Participants 26 1 10/60 4 Affiliat Institution without an IRB Participants 20 1 20/60 40 Local Context Participants 120 1 20/60 40 Local Context Participants 120 1 20/60 40 Study Closure or Transfer Of Study Review P Participants 120 1 10/60 20 Continuing Noncompliance Reprints Form. 120 1 10/60 20 10/60 20 Add or Renove Affiliate Institution Participants 120 1 10/60 20 10/60 20 10/60 20 10/60 20 10/60 20 10/60 20	Institutional Contact for Signatory Institution	Participants	65	1	10/60	11
IFB at Affliate Institution		Participants				-
Affiliate Institution without an IRB Participants 25 1 10/60 50 Study Review Responsibility Transfer Form Participants 300 1 10/60 50 Study Review Responsibility Transfer Form Participants 80 1 10/60 40 Annal Signatory Institution Worksheet About Local Context Participants 120 1 20/60 40 Study Specific Worksheet About Local Context Participants 120 1 10/60 20 Study Specific Worksheet About Local Context Participants 120 1 10/60 20 Study Specific Worksheet About Local Context Participants 120 1 10/60 20 Ad or Remove Signatory androit Nithion Personnel Participants 120 1 10/60 20 Change of Signatory institution P Form Participants 120 1 10/60 20 Change of Signatory institution P Form Participants 120 1 10/60 20 Change of Signatory institution P Form Participants						
Facilitated Review Acceptance Form Participants 300 1 10/60 13 Annual Signatory Institution Worksheet About Participants 120 1 20/60 40 Annual Signatory Institution Worksheet About Participants 120 1 20/60 40 Annual Signatory Institution Worksheet About Participants 120 1 20/60 73 Study Closure or Transfer of Study Review Responsibility Transfer of Study Review Responsibility Transfer of Study Review Responsibility Transfer Component Institution Participants 10 10/60 20 Add or Remove Signatory Institution Participants 120 1 10/60 20 Add or Remove Component Institution Participants 120 1 10/60 20 CIRB Board Member Contact Information Form Participants 120 1 10/60 20 CIRB Board Member Non-Disclosure Agreemem Board Members 25 1 16/60 4 CIRB Board Member Non-Disclosure Agreemem Board Members 25 1 16/60 4 1 6						
Study Review Responsibility Transfer Form Participants 80 1 1060 13 Annual Signatory Institution Worksheet About Local Cortext. Participants 120 1 2060 40 Annual Signatory Anticipantel Provincipantel Provinci Provincipantel Provincipantel Provincipantel Provincipant						
Annial Signatory Institution Worksheet About Local Context. 120 1 2060 40 Annual Principal Investigator Worksheet About Local Context. 120 1 2060 40 Study Specific Worksheet About Local Context. Participants 220 1 2060 73 Study Cosume or Transfer of Study Review Reporting Form. Participants 220 1 2060 73 Add or Remove Signatory and/or Component Institution Personnel. Participants 120 1 10/60 20 Add or Remove Component Institution Participants 120 1 10/60 20 Charlow Foll Over Worksheet Participants 120 1 10/60 20 Charlow Foll Over Worksheet Participants 120 1 10/60 20 Charlow Foll Over Worksheet Participants 120 1 10/60 20 Charlow Foll Over Worksheet Participants 20 1 10/60 20 Charlow Foll Over Worksheet Participants 20 1 10/60 20 <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td></tr<>						
Local Context. 120 1 20/60 40 Annual Principal Investigator Worksheet About Local Context. Participants 120 1 20/60 40 Study Specific Worksheet About Local Context Participants 120 1 10/60 20 Study Specific Worksheet About Local Context Participants 120 1 10/60 20 Continuing Noncompliance Reporting Form. Participants 120 1 10/60 20 Add or Remove Signatory and/or Component Institution Participants 120 1 10/60 20 Add or Remove Camponent Institution Participants 120 1 10/60 20 Add or Remove Camponent Institution Participants 120 1 10/60 20 CIRB Board Member Non-Disclosure Agreement (NDA). CIRB Board Member Contact Information Form Board Members 25 1 10/60 20 CIRB Board Member Non-Disclosure Agreement (NDA). CIRB Board Member Non-Disclosure Agreement (NDA). 20 30/60 40 30/60 40 30/60 40	, , ,					
Annual Principal Investigator Worksheet About Local Context. Participants 120 1 2060 40 Study-Specific Worksheet About Local Context. Participants 220 1 2060 73 Study-Specific Worksheet About Local Context. Participants 120 1 10/60 20 Sponsibility Form. Porticipants 120 1 10/60 20 Porticipants 120 1 10/60 20 Participants 120 1 10/60 20 Add or Remove Affiliate Institution Personnel Participants 120 1 10/60 20 Charge of Signatory Institution PI Form Participants 120 1 10/60 20 Charge of Signatory Institution Form Board Members 25 1 10/60 20 CHB Board Member Wo-Disclosure Agreement Board Members 25 1 10/60 20 CHB Board Member Wo-Disclosure Agreement Board Members 25 1 10/60 20 CHB Board Member Wo-Disclosure Agreement <td>o ,</td> <td>Participants</td> <td>120</td> <td>I</td> <td>20/60</td> <td>40</td>	o ,	Participants	120	I	20/60	40
Study-Specific Worksheet About Load Context Participants	Annual Principal Investigator Worksheet About	Participants	120	1	20/60	40
Study Closure or Transfer of Study Review Re- sponsibility Form.Participants120110/6020Potential Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form.Participants120115/6030Add or Remove Signatory and/or Component Insti- tution Personnel.Participants120110/6020Add or Remove Affiliate InstitutionParticipants120110/6020Add or Remove Affiliate InstitutionParticipants120110/6020Add or Remove Affiliate InstitutionParticipants120110/6020One Time Study Roll Over WorksheetParticipants120110/6020Change of Signatory Institution PI FormBoard Members25115/60620CIRB Board Member Roll Organitial Sketch FormBoard Members25115/6064CIRB Board Member Von-Disclosure Agreement25115/6066CIRB Board Member Von-Disclosure Agreement25115/6064CIRB Board Member Von-Disclosure Agreement25115/6066Sutdies26115/60666CIRB Board Member Von-Disclosure Agreement2611220NCI Adult/Pediatric CIRB Application for Con- tuning ReviewParticipants20130/6010Cocally-Develored Material Submission FormParticipants151 <td< td=""><td></td><td>Participants</td><td>220</td><td>1</td><td>20/60</td><td>73</td></td<>		Participants	220	1	20/60	73
sponsibility Form.120115/60Potential Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form.120110/6020Add or Remove Signatory and/or Component Insti- tution Personnel.120110/6020Add or Remove Component InstitutionParticipants120110/6020Add or Remove Component InstitutionParticipants120110/6020One Time Study Roll Over WorksheetParticipants120110/6020Change of Signatory InstitutionParticipants120110/6020Change of Signatory InstitutionParticipants120110/6020Change of Signatory InstitutionParticipants120110/6020Change of Signatory InstitutionParticipants120110/6020CIRB Board Member Contact Information FormBoard Members25115/606CIRB Board Member V-9Contact Members25115/606CIRB Board Member Ander Disclosure AgreementBoard Members25115/606NCI Adult/Pediatric CIRB Application for Ancillary Studies101220Summary of CIRB Application for Ancillary Studies20130/6010Coally Developed Material Submission Form151460Participants151460Coally Developed Material Submission Form51 </td <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td>			-			
Potential Unanticipated Problem or Serious or Continuing Nencompliance Reporting Form. 120 1 15/60 30 Add or Remove Signatory and/or Component Institution Personnel. Participants 120 1 10/60 20 Add or Remove Affiliate Institution Personnel. Participants 120 1 10/60 20 Add or Remove Affiliate Institution Participants 120 1 10/60 20 Add or Remove Affiliate Institution PForm Participants 120 1 10/60 20 Change of Signatory Institution PF Form Participants 120 1 10/60 20 ChiB Board Member Storgaphical Sketch Form Board Members 25 1 15/60 6 CHB Board Member Von-Disclosure Agreement Board Members 25 1 10/60 4 CHB Adult/Pediatric CIRB Application for Ancillary Participants 10 1 2 20 Summary of CIRB Application Ferview Participants 10 1 2 20 Summary of CIRB Application Ferview Participants 10 1 30/60 10 1 30/60 10 <td></td> <td></td> <td>120</td> <td>•</td> <td>10,00</td> <td>20</td>			120	•	10,00	20
Continuing Noncompliance Reporting Form. Add or Remove Signatory and/or Component Institution ParticipantsParticipants120110/6020Add or Remove Component Institution Add or Remove Component Institution Add or Remove Component Institution Add or Remove Component Institution Participants120110/6020Add or Remove Component Institution Component Institution Change of Signatory Institution PF Form CIRB Board Member Sc CIRB Board Member Contact Information FF Form CIRB Board Member Sc CIRB Board Member Contact Information FF Form CIRB Board Member Sc ES110/6020CIRB Board Member Contact Information Form (NDA)Board Members Board Members25110/604CIRB Doard Member Contact Information Form StudiesBoard Members Board Members25110/604CIRB Doard Member Contact Information For NCI Adult/Pediatric CIRB Application for Treatment StudiesBoard Members Board Members2511/606NCI Adult/Pediatric CIRB Application for Con- truing Review of Cooperative Group Protocol tocol.Participants20130/6010Quality Deview of Cooperative Group Protocol reduintic Review of Cooperative Group Pro- tocol.Participants1001220Pediatric Corperative Group Protocol reduintic Cooperative Group Protocol reduintic Review of Cooperative Group Pro- tocol.Board Members1001220Pediatric Cooperative Group Response to CIRB review.Board Members1001220P		Participants	120	1	15/60	30
Add or Remove Signatory and/or Component Institution tution Personnel.Participants120110/6020Add or Remove Affiliate Institution Personnel and or Remove Component Institution Participants120110/6020Add or Remove Affiliate Institution One Time Study Poll Over Worksheet CHB Board Member Signatory Institution PI Form CIRB Board Member Signatory Institution PI Form CIRB Board Member Signatory Institution PI Form CIRB Board Member Contact Information Form Board Members120110/6020CIRB Board Member Contact Information Form Studies.Board Members Board Members25115/606CIRB Board Member Von-Disclosure Agreement NCI Adult/Pediatric CIRB Application for Ancillary Studies.Board Members Participants25115/606CI Adult/Pediatric CIRB Application for Ancillary Studies.Participants20130/6010NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants20130/6010NCI Adult/Pediatric CIRB Application for Con- truing Review.Participants20130/6010Locally-Developed Material Submission Form rents.Participants101220Adult Torlinal Review of Cooperative Group Protocol rotocl.Board Members151460Pediatric Initial Review of Cooperative Group Pro- tocol.Board Members101220Adult Amendment of Cooperative Group Pro- tocol.Board Members1012 <td>1</td> <td></td> <td></td> <td>•</td> <td></td> <td></td>	1			•		
tution Personnel. Participants 120 1 10/60 20 Add or Remove Component Institution Participants 120 1 10/60 20 Add or Remove Component Institution Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 CIRB Board Member Contact Information FForm Board Members 25 1 10/60 4 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Doard Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Doard Member Non-Disclosure Agreement Board Members 25 1 15/60 6 NCI Adult/Pediatric CIRB Application for Ancillary Participants 20 1 30/60 10 Summary of CIRB Application Revisions Participants 20 1 30/60 10 Locally-Developed Material Submission Form Participants 15 1 15/60		Participants	120	1	10/60	20
Add or Remove Component Institution Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 CIRB Board Member Biographical Sketch Form Board Members 25 1 15/60 6 25 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Doard Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Doard Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRD Adult/Pediatric CIRB Application for Treatment Board Members 25 1 10/60 4 NCI Adult/Pediatric CIRB Application for Contuning Review Participants 10 1 2 20 1 30/60 10 Summary of CIRB Application Revisions Participants 15 1 5/60 4 60 1 10 10 1 2 20 1 30/60 10 <t< td=""><td></td><td></td><td>-</td><td></td><td></td><td></td></t<>			-			
Add or Remove Component Institution Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 CIRB Board Member Biographical Sketch Form Board Members 25 1 10/60 4 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRD Adult/Pediatric CIRB Application for Treatment Board Members 25 1 10/60 4 CIRD Adult/Pediatric CIRB Application for Com- tinuing Review Board Members 25 1 1 20 Surdies 20 1 30/60 10 1 2 20 Surdies 20 1 30/60 10 1 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16	Add or Remove Affiliate Institution Personnel	Participants	120	1	10/60	20
One Time Study Roll Over Worksheet Participants 120 1 10%60 20 Change of Signatory Institution PI Form Participants 120 1 10%60 20 CIRB Board Member Biographical Sketch Form Board Members 25 1 15%60 6.25 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10%60 4 CIRB Direct Deposit Form Board Members 25 1 10%60 4 CIAB Direct Deposit Form Board Members 25 1 10%60 4 CIAdult/Pediatric CIRB Application for Treatment Studies. 10 1 2 20 NCI Adult/Pediatric CIRB Application for Contituing Review. Participants 10 1 2 20 Summary of CIRB Application Revisions Participants 10 1 2 20 Valut Inditial Review of Cooperative Group Protocol Participants 10 1 10 10 Pediatric Initial Review of Cooperative Group Protocol Board Members 10 1 10 <td>Add or Remove Component Institution</td> <td></td> <td>120</td> <td>1</td> <td>10/60</td> <td>20</td>	Add or Remove Component Institution		120	1	10/60	20
Change of Signatory Institution PI FormParticipants120110/6020CIRB Board Member Contact Information FormBoard Members25115/606.25CIRB Board Member Non-Disclosure AgreementCoard Members25110/604CIRB Direct Deposit FormBoard Members25110/604CIRB Direct Deposit FormBoard Members25110/604CIRB Direct Deposit FormBoard Members251250NCI Adult/Pediatric CIRB Application for TreatmentBoard Members251220NCI Adult/Pediatric CIRB Application for Continuing ReviewParticipants20130/6010Sundies20130/60102020Sundies20130/60102020Sundies20130/60102020Sundies20130/60102020Coally-Devideed Material Submission FormParticipants15115/604Application Request to Review translated Documents151460Protocol.Adult Initial Review of Cooperative Group Protocol.Board Members1011100Protocol.Board Members101220202020Adult Cooperative Group Protocol.Board Members1012202020Protocol.Adult Cooper	Add or Remove Affiliate Institution		120	1	10/60	20
CIRB Soard Member Biographical Sketch Form Board Members 25 1 15/60 6.25 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Board Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Dard Member Non-Disclosure Agreement Board Members 25 1 10/60 4 CIRB Dard LiPediatric CIRB Application for Treatment Studies. 25 1 15/60 6 NCI Adult/Pediatric CIRB Application for Ancillary Studies. 10 1 2 20 Summary of CIRB Application Revisions Participants 20 1 30/60 10 Participants 15 1 5/60 4 60 Participants 10 1 2 20 Noti Adult/Pediatric Initial Review of Cooperative Group Protocol Participants 10 1 10 Pediatric Continuing Review of Cooperative Group Protocol Board Members 10 1 1 10 Pediatric Continuing Review of Cooperative Group Protocol Board Members 10 1 <	One Time Study Roll Over Worksheet	Participants	120	1	10/60	20
CIRB Board Member Contact Information Form (NDA).Board Members Board Members25110/604CIRB Board Member Non-Disclosure Agreement (NDA).Board Members 	Change of Signatory Institution PI Form	Participants	120	1	10/60	20
CI-RB Board Member W-9Board Members25115/606CIRB Board Member Non-Disclosure AgreementBoard Members25110/604CIRB Direct Deposit FormBoard Members2511250Studies.CIRB Application for TreatmentParticipants251220NCI Adult/Pediatric CIRB Application for AncillaryParticipants101220Studies.NCI Adult/Pediatric CIRB Application for Con- tinuing Review.Participants20130/60100Summary of CIRB Application Reviews of Cooperative Group Protocol.Participants151460Adult Initial Review of Cooperative Group Protocol.Board Members151460Pediatric Continuing Review of Cooperative Group Protocol.Board Members101220Adult Amendment of Cooperative Group Protocol.Board Members101220Adult Continuing Review of a Cooperative Group Protocol.Board Members101220Pediatric Continuing Review of a Cooperative Group Protocol.Board Members101220Pediatric Continuing Review of a Cooperative Group Protocol.Board Members101220Pediatric Continuing Review of a Cooperative Group Response to CIRB Review.30111010Pediatric Continuing Noncompliance (SCN).Board Members20122020Pediatric Co	CIRB Board Member Biographical Sketch Form	Board Members	25	1	15/60	6.25
CIRB Board Member Non-Disclosure Agreement (NDA).Board Members25110/604(NDA).Board Members25115/606NCI Adult/Pediatric CIRB Application for Treatment Studies.Board Members251250NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCI Adult/Pediatric CIRB Application for Con- tinuing Review.Participants801180Summary of CIRB Application RevisionsParticipants15115/604Application Request to Review Translated Docu- ments.Participants151460Pedicipants151460606060Pedicitic Initial Review of Cooperative Group Protocol tocol.Board Members151460Pediatric Continuing Review of Cooperative Group Protocol.80111100Pediatric Continuing Review of Cooperative Group Protocol.80111100Pediatric Continuing Review of Cooperative Group Protocol.80101220Board Members101220202020Adult Continuing Review of a Cooperative Group Protocol.80101220Board Members10122020202020Cool.909011110102020 </td <td>CIRB Board Member Contact Information Form</td> <td>Board Members</td> <td>25</td> <td>1</td> <td>10/60</td> <td>4</td>	CIRB Board Member Contact Information Form	Board Members	25	1	10/60	4
(NDA).Board Members25115/606CIRB Direct Deposit FormParticipants251250Studies.NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCI Adult/Pediatric CIRB Application for Con- triuning Review.Participants801180Summary of CIRB Application RevisionsParticipants20130/6010Locally-Developed Material Submission FormParticipants15115/604Application Request to Review Translated Docu- ments.151460Decidiatric Initial Review of Cooperative Group Protocol Protocol.Board Members151460Adult Continuing Review of Cooperative Group Protocol.Board Members10011100Protocol.Board Members101220Adult Amendment of Cooperative Group Protocol rocol.Board Members101220Pediatric Continuing Review of a Cooperative Group Protocol.Board Members101220Adult Amendment of Cooperative Group Protocol.Board Members101110Pediatric Cooperative Group Response to CIRB Review.Participants101220View.Pediatric Cooperative Group Response to CIRB Participants10<						
NCI Adult/Pediatric CIRB Application for Treatment Studies.Participants251250NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCI Adult/Pediatric CIRB Application for Con- tinuing Review.Participants8011180Summary of CIRB Application RevisionsParticipants20130/60100Locally-Developed Material Submission Form ments.Participants20130/60100Adult Initial Review of Cooperative Group Protocol Protocol.Board Members151460Pediatric Continuing Review of Cooperative Group Protocol.Board Members130111300Adult Continuing Review of Cooperative Group Protocol.Board Members101220Pediatric Continuing Review of Cooperative Group Protocol Protocol.Board Members1011100Pediatric Cooperative Group Response to CIRB Review.Cooperative Group Response to CIRB Review.1011110Pediatric Cooperative Group Response to CIRB Review.Board Members101220Study.Board Members10122020Cool.Adult Pharmacist's Review of a Cooperative Group Review.Board Members101110Review.Group Study.Board Members30130/601520CIRB Statistical Review FormBoar	(NDA).			1		4
Studies.NCIAdult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCIAdult/Pediatric CIRB Application for Con- tinuing Review.Participants801180Summary of CIRB Application RevisionsParticipants20130/6010Locally-Developed Material Submissions FormParticipants15115/604Adult Initial Review of Cooperative Group ProtocolBoard Members151460Pediatric Initial Review of Cooperative Group Protocol.Board Members151460Protocol.Board Members151460Protocol.Board Members101220Adult Continuing Review of Cooperative Group Protocol.Board Members101220Adult Cooperative Group ProtocolBoard Members101220Adult Cooperative Group Review of Cooperative Group Protocol.Board Members101220Adult Cooperative Group Response to CIRB Review.Participants101220View.Pediatric Pharmacist's Review of a Cooperative Group Study.1011101220Pediatric Pharmacist's Review of a Cooperative Group Study.101220201220CIRB Statistical Reviewer FormBoard Members201240201220 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
NCI Adult/Pediatric CIRB Application for Ancillary Studies.Participants101220NCI Adult/Pediatric CIRB Application for Con- tinuing Review.Participants8011180Summary of CIRB Application RevisionsParticipants20130/60100Locally-Developed Material Submission FormParticipants15115/604Application Request to Review Translated Docu- ments.15115/604Adult Initial Review of Cooperative Group Protocol tocol.Board Members151460Pediatric Initial Review of Cooperative Group Protocol. Protocol.Board Members13011130Pediatric Continuing Review of Cooperative Group Protocol.Board Members101220Adult Continuing Review of Cooperative Group Protocol. rotocol.Board Members101220Adult Cooperative Group Response to CIRB Review.Participants101110Adult Cooperative Group Response to CIRB Review.Participants101110Adult Continuing Neview of a Cooperative Group Study.Board Members201220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201110Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201220CHRB Statistical Reviewer FormBoard Members30130/		Participants	25	1	2	50
NCI Adult/Pediatric CIRB Application for Continuing Review.Participants801180Summary of CIRB Application RevisionsParticipants20130/6010Locally-Developed Material Submission FormParticipants15115/604Application Request to Review Translated Documents.15115/604Adult Initial Review of Cooperative Group ProtocolBoard Members151460Pediatric Initial Review of Cooperative Group Protocol.Board Members13011130Pediatric Initial Review of Cooperative Group Protocol.Board Members1001220Adult Continuing Review of Cooperative Group Protocol.Board Members101220Pediatric Continuing Review of Cooperative Group Protocol.Board Members101220Adult Cooperative Group Response to CIRB Review.10122020Adult Cooperative Group Response to CIRB Review.101110102Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members300130/6015Adult Expedited Amendment ReviewBoard Members350130/607536	NCI Adult/Pediatric CIRB Application for Ancillary	Participants	10	1	2	20
Summary of CIRB Application RevisionsParticipants20130/6010Locally-Developed Material Submission FormParticipants15115/604Application Request to Review Translated DocumersParticipants15115/604Adult Initial Review of Cooperative Group ProtocolBoard Members151460Pediatric Initial Review of Cooperative Group Protocol.Board Members130111300Adult Continuing Review of Cooperative Group Protocol.Board Members130111300Pediatric Continuing Review of Cooperative Group Protocol.Board Members101220Adult Cooperative Group Protocol.Board Members101220Adult Cooperative Group Response to CIRB Review.Board Members101110Pediatric Charmacist's Review of a Cooperative Group Study.Participants101110Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members30130/6015Determination of Unanticipated Problem (UP) and or Serious or Continuing Noncompliance (SCN).Board Members350130/60175Adult Expedited Amendment ReviewBoard Members350130/607530/6075Board Members120130/60607630/6060<	NCI Adult/Pediatric CIRB Application for Con-	Participants	80	1	1	80
Locally-Developed Material Submission FormParticipants15115/604Application Request to Review Translated Documents.Participants15115/604Adult Initial Review of Cooperative Group ProtocolBoard Members151460Pediatric Initial Review of Cooperative Group Protocol.Board Members151460Protocol.Board Members130111130Pediatric Continuing Review of Cooperative Group Protocol.Board Members7011220Pediatric Amendment of Cooperative Group Protocol.Board Members10122020Pediatric Cooperative Group Response to CIRB Review.1012201220Pediatric Pharmacist's Review of a Cooperative Group Response to CIRB Review.Participants1011101110Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201220		Participants	20	1	30/60	10
Application Request to Review Translated Documents.Participants15115/604Modult Initial Review of Cooperative Group ProtocolBoard Members151460Pediatric Initial Review of Cooperative Group Protocol.Board Members151460Adult Continuing Review of Cooperative GroupBoard Members13011130Pediatric Continuing Review of Cooperative GroupBoard Members130111130Protocol.Board Members101220Adult Amendment of Cooperative Group ProtocolBoard Members101220Board Members101220Board Members101220Board Members101110Pediatric Cooperative Group Response to CIRB Review.Participants101110Review.Group Study.Board Members201220Claritic Pharmacist's Review of a Cooperative Group Study.Board Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members350130/6075Adult Expedited Continuing ReviewBoard Members350130/607530/6075Ped Expedited Continuing ReviewBoard Members70130/606075Board Members70130/606075						
Adult Initial Review of Cooperative Group Protocol Pediatric Initial Review of Cooperative Group Pro- tocol.Board Members151460Adult Continuing Review of Cooperative Group Protocol.Board Members151460Adult Continuing Review of Cooperative Group Protocol.Board Members130111130Pediatric Continuing Review of Cooperative Group Protocol.Board Members1001220Adult Amendment of Cooperative Group ProtocolBoard Members101220Adult Cooperative Group Response to CIRB Review.Participants1511110Adult Pharmacist's Review of a Cooperative Group Study.CIRB Statistical Review of a Cooperative Group Study.Participants201220Pediatric Continuing Noncompliance (SCN).Board Members30130/6015Adult Expedited Amendment ReviewBoard Members350130/60175Pediatric Continuing ReviewBoard Members350130/6060Ped Expedited Continuing ReviewBoard Members150130/6060Ped Expedited Continuing ReviewBoard Members120130/6060	Application Request to Review Translated Docu-					
Pediatric Initial Review of Cooperative Group Pro- tocol.Board Members151460Adult Continuing Review of Cooperative Group Protocol.Board Members13011130Pediatric Continuing Review of Cooperative Group Protocol.Board Members7011130Pediatric Continuing Review of Cooperative Group Protocol.Board Members7011220Board Members101220202020202020Pediatric Amendment of Cooperative Group Pro- tocol.Board Members1012202		Board Members	15	1	4	60
tocol.Board Members13011130Adult Continuing Review of Cooperative Group Protocol.Board Members13011130Pediatric Continuing Review of Cooperative Group Protocol.Board Members7011170Adult Amendment of Cooperative Group Protocol.Board Members101220Pediatric Amendment of Cooperative Group Protocol.Board Members101220Adult Cooperative Group Response to CIRB Review.Participants1511115Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220CIRB Statistical Reviewer FormBoard Members201220Board Members30130/601515Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members350130/60175Board Members150130/607530/607530/6060Ped Expedited Amendment ReviewBoard Members150130/6060Ped Expedited Continuing ReviewBoard Members120130/6035	Pediatric Initial Review of Cooperative Group Pro-	Board Members	15	1	4	60
Protocol.Board Members701170Pediatric Continuing Review of Cooperative Group Protocol.Board Members7011220Adult Amendment of Cooperative Group Protocol.Board Members101220Pediatric Amendment of Cooperative Group Protocol.Board Members101220Board Members101220Board Members101220Adult Cooperative Group Response to CIRB Review.Participants15111Pediatric Cooperative Group Response to CIRB Review.Participants101220Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240Group Study.Board Members30130/60155Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members350130/60175Ped Expedited Amendment ReviewBoard Members350130/607566066060606035						
Protocol.Board Members101220Adult Amendment of Cooperative Group ProtocolBoard Members101220Pediatric Amendment of Cooperative Group Protocol.Board Members101220Adult Cooperative Group Response to CIRB Review.Participants151115Pediatric Cooperative Group Response to CIRB Review.Participants101110Review.Board Members101220Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201220CIRB Statistical Reviewer FormBoard Members201240Or Serious or Continuing Noncompliance (SCN).Board Members30130/6015Adult Expedited Amendment ReviewBoard Members350130/60175Ped Expedited Continuing ReviewBoard Members150130/6060Ped Expedited Continuing ReviewBoard Members120130/6060	5 1 1	Board Members	130	1	1	130
Pediatric Amendment of Cooperative Group Pro- tocol.Board Members101220Adult Cooperative Group Response to CIRB Re- view.Participants1511115Pediatric Cooperative Group Response to CIRB Review.Participants101110Adult Pharmacist's Review of a Cooperative Group Study.Participants101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members101220Board Members10122020Board Members101220Board Members101220Board Members101220Board Members101220Board Members201240Board Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members40110/60Adult Expedited Amendment ReviewBoard Members350130/60175Board Members150130/606060Ped Expedited Continuing Review50130/6060Board Members70130/6035	Protocol.		70	1		70
Adult Cooperative Group Response to CIRB Review.Participants151115Pediatric Cooperative Group Response to CIRB Review.Participants101110Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240CIRB Statistical Reviewer FormBoard Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members350130/60175Adult Expedited Amendment ReviewBoard Members150130/607530/6075Ped Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035	Pediatric Amendment of Cooperative Group Pro-					
Pediatric Cooperative Group Response to CIRB Review.Participants101110Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240CIRB Statistical Reviewer Form Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members30130/6015Adult Expedited Amendment Review Adult Expedited Continuing ReviewBoard Members350130/60175Board Members Board Members350130/607530/6075Adult Expedited Continuing Review Ped Expedited Continuing Review120130/6060Board Members70130/603535	Adult Cooperative Group Response to CIRB Re-	Participants	15	1	1	15
Adult Pharmacist's Review of a Cooperative Group Study.Board Members101220Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240CIRB Statistical Reviewer Form Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members30130/6015Adult Expedited Amendment Review Ped Expedited Continuing ReviewBoard Members40110/607Board Members Board Members350130/60175150Ped Expedited Continuing Review Ped Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members120130/6035	Pediatric Cooperative Group Response to CIRB	Participants	10	1	1	10
Pediatric Pharmacist's Review of a Cooperative Group Study.Board Members201240Group Study.CIRB Statistical Reviewer FormBoard Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members40110/607Adult Expedited Amendment ReviewBoard Members350130/60175Ped Expedited Continuing ReviewBoard Members150130/6060Ped Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035	Adult Pharmacist's Review of a Cooperative Group	Board Members	10	1	2	20
CIRB Statistical Reviewer FormBoard Members30130/6015Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members40110/607Adult Expedited Amendment ReviewBoard Members350130/60175Ped Expedited Amendment ReviewBoard Members150130/6075Adult Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035	Pediatric Pharmacist's Review of a Cooperative	Board Members	20	1	2	40
Determination of Unanticipated Problem (UP) and/ or Serious or Continuing Noncompliance (SCN).Board Members40110/607Adult Expedited Amendment ReviewBoard Members350130/60175Ped Expedited Amendment ReviewBoard Members150130/6075Adult Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035		Board Members	30	1	30/60	15
Adult Expedited Amendment ReviewBoard Members350130/60175Ped Expedited Amendment ReviewBoard Members150130/6075Adult Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035	Determination of Unanticipated Problem (UP) and/					
Ped Expedited Amendment ReviewBoard Members150130/6075Adult Expedited Continuing ReviewBoard Members120130/6060Ped Expedited Continuing ReviewBoard Members70130/6035		Board Members	350	1	30/60	175
Ped Expedited Continuing ReviewBoard Members70130/6035		Board Members	150	1	30/60	75
		Board Members	120	1	30/60	
Adult Expedited Study Closure Board Members 20 1 20/60 7						
	Adult Expedited Study Closure	Board Members	20	1	20/60	7

Form name	Type of respondents	Number of respondents	Frequency of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Ped Expedited Study Closure Adult Expedited Study Chair Response to Re- guired Mod.	Board Members Board Members	20 350	1	20/60 15/60	7 88
Ped Expedited Study Chair Response to Required Mod.	Board Members	150	1	15/60	38
Reviewer Worksheet of Translated Documents Reviewer Advertisement Checklist	Board Members Board Members	15 10	1	15/60 20/60	4 3

ESTIMATES OF ANNUAL BURDEN HOURS—Continued

Dated: November 7, 2013.

Vivian Horovitch-Kelley, Program Analyst, National Institutes of

Health. [FR Doc. 2013–27556 Filed 11–18–13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request: Cancer Trials Support Unit (CTSU) (NCI)

SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on August 30, 2013, Vol. 78, p. 53763 and allowed 60days for public comment. There have been no public comments. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@ omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments or request more information on the proposed project contact: Michael Montello, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, 9609 Medical Center Drive, Rockville, MD 20850 or call non-toll-free number 240–276–6080 or Email your request, including your address to: *montellom@ mail.nih.gov.* Formal requests for additional plans and instruments must be requested in writing.

Proposed Collection: Cancer Trials Support Unit (CTSU) (NCI), 0925–0624, Expiration Date 12/31/2013, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information Collection: The Cancer Therapy Evaluation Program (CTEP) establishes and supports programs to facilitate the participation of qualified investigators on CTEP-supported studies, and to institute programs that minimize redundancy among grant and contract holders, thereby reducing overall cost of maintaining a robust treatment trials program. Currently guided by the efforts of the Clinical Trials Working Group (CTWG) and the Institute of Medicine (IOM) recommendations to revitalize the Cooperative Group program, CTEP has funded the Cancer Trials Support Unit (CTSU). The CTSU collects standardized forms to process site regulatory information, changes to membership, patient enrollment data, and routing information for case report forms. In addition, CTSU collects annual surveys of customer satisfaction for clinical site staff using the CTSU Help Desk, the CTSU Web site, and the Protocol and Information Office (PIO). An ongoing user satisfaction survey is in place for the Oncology Patient Enrollment Network (OPEN). User satisfaction surveys are compiled as part of the project quality assurance activities and are used to direct improvements to processes and technology. Additionally, there are three surveys that collect information about health professional's interests in clinical trial, potential issues with opening and accruing to a clinical trial and reasons for low accrual.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 25,205.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hour
CTSU IRB/Regulatory Approval Transmittal Form	Health Care Practitioner	9,000	12	2/60	3,600
CTSU IRB Certification Form	Health Care Practitioner	8,500	12	10/60	17,000
CTSU Acknowledgement	Health Care Practitioner	500	12	5/60	500
Withdrawal from Protocol Participation Form	Health Care Practitioner	50	12	5/60	50
Site Addition	Health Care Practitioner	25	12	5/60	25
CTSU Roster Update Form	Health Care Practitioner	50	12	4/60	40
CTSU Radiation Therapy Facilities Inventory	Health Care Practitioner	20	12	30/60	120
Form.					